NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Safety and Effectiveness of the Vaccine ALVAC-HIV vCP205 in HIV-Negative Adult Volunteers in Uganda

Phase 1

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-01

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 40

Registration Number: NCT00007423

Locations: 🇺🇬
UVRI - IAVI HIV Vaccine Program, Entebbe, Uganda
🇺🇬
Joint Clinical Research Center N09-002 CRS, Kampala, Uganda

A Multicenter, Randomized, Placebo-Controlled, Double-Blinded, Phase I Trial to Evaluate the Safety and Immunogenicity of Live Recombinant Canarypox ALVAC-HIV vCP205 Combined With GM-CSF in Healthy, HIV-1 Uninfected Volunteers

Phase 1

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-01

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 36

Registration Number: NCT00001090

Locations: 🇺🇸
UAB AVEG, Birmingham, Alabama, United States
🇺🇸
Univ. of Rochester AVEG, Rochester, New York, United States
🇺🇸
JHU AVEG, Baltimore, Maryland, United States

and more 1 locations

Safety and Effectiveness of the Selegiline "Patch" for Decreased Mental Function in HIV Patients

Phase 2

Completed

Conditions: HIV Infections
Cognition Disorders

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-01

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 127

Registration Number: NCT00013585

Locations: 🇺🇸
UCLA CARE Center CRS, Los Angeles, California, United States
🇺🇸
Johns Hopkins Adult AIDS CRS, Baltimore, Maryland, United States
🇺🇸
Univ. of Hawaii at Manoa, Leahi Hosp., Honolulu, Hawaii, United States

and more 12 locations

Effects of BufferGel and PRO 2000/5 Gel in Men

Phase 1

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-01

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 24

Registration Number: NCT00016536

Locations: 🇺🇸
UW HIV Prevention CRS, Seattle, Washington, United States

A Phase I Safety and Immunogenicity Trial of HIV-1 gp120 C4-V3 Hybrid Polyvalent Peptide Immunogen Mixed in Mineral Oil Containing Mannose Mono-Oleate (IFA)

Phase 1

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-10-29

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 24

Registration Number: NCT00000886

Locations: 🇺🇸
UW - Seattle AVEG, Seattle, Washington, United States
🇺🇸
Vanderbilt Univ. Hosp. AVEG, Nashville, Tennessee, United States
🇺🇸
Univ. of Rochester AVEG, Rochester, New York, United States

A Phase I/II Double-Blind Controlled Trial to Determine the Safety and Immunogenicity of HIV-1 MN rgp160 Immuno AG Vaccine Therapy in HIV-Infected Individuals With Greater Than or Equal to 500/mm3 CD4+ T Cells and 200-400/mm3 CD4+ T Cells

Phase 1

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-10-29

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 46

Registration Number: NCT00000822

Locations: 🇺🇸
Stanford CRS, Stanford, California, United States

A Study to Test If Giving Remune (an HIV Vaccine) Can Improve the Immune Systems of HIV-Positive Patients Who Are Also Participating in ACTG 328

Not Applicable

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-10-29

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 50

Registration Number: NCT00000943

Locations: 🇺🇸
Univ. of Iowa Healthcare, Div. of Infectious Diseases, Iowa City, Iowa, United States
🇺🇸
NY Univ. HIV/AIDS CRS, New York, New York, United States

A Study of Dideoxyinosine (ddI) in HIV-Infected Children Who Have Not Had Success With Zidovudine or Who Cannot Take Zidovudine

Phase 2

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-10-29

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 300

Registration Number: NCT00000963

Locations: 🇺🇸
Emory Univ. School of Medicine, Dept. of Peds., Div. of Infectious Diseases, Atlanta, Georgia, United States
🇺🇸
Cook County Hosp., Chicago, Illinois, United States
🇺🇸
Univ. of Illinois College of Medicine at Chicago, Dept. of Peds., Chicago, Illinois, United States

and more 49 locations

A Randomized Trial of the Efficacy and Safety of a Strategy of Starting With Nelfinavir Versus Ritonavir Added to Background Antiretroviral (AR) Nucleoside Therapy in HIV-Infected Individuals With CD4+ Cell Counts Less Than or Equal to 200/mm3

Not Applicable

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-10-29

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 1300

Registration Number: NCT00000859

Locations: 🇺🇸
AIDS Research Consortium of Atlanta, Atlanta, Georgia, United States
🇺🇸
AIDS Research Alliance - Chicago, Chicago, Illinois, United States
🇺🇸
Baltimore TRIALS, Baltimore, Maryland, United States

and more 40 locations

A Study on the Effect of Chemotherapy Combined With Anti-HIV Drugs in HIV-Positive Patients

Phase 1

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-10-29

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 10

Registration Number: NCT00000899

Locations: 🇺🇸
Univ of North Carolina, Chapel Hill, North Carolina, United States
🇺🇸
Duke Univ Med Ctr, Durham, North Carolina, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy